SPY754.09−0.75%QQQ680.97−1.36%BTC/USD72,566.14−1.84%DIA522.37−0.39%GLD359.37−1.59%TLT80.40−0.64%

Viking Therapeutics Inc

VKTXNASDAQ

Trade with Public

$28.44

-0.22-0.77%

Last update: Nov 12, 8:13 AM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Viking Therapeutics (VKTX) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Viking Therapeutics (VKTX) stock.

Analyst Consensus — 18 Analysts

16Buy

2Hold

# Analysts18

Latest Upgrades and Downgrades for Viking Therapeutics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Canaccord Genuity	Edward Nash	PT Raise	Buy	$106→$118
—	Canaccord Genuity	Edward Nash	PT Cut	Buy	$114→$106
—	UBS	Joon Lee	Initiate	Buy	$94
—	Truist Securities	Joon Lee	PT Cut	Buy	$87→$85
—	Truist Securities	Joon Lee	PT Raise	Buy	$83→$87
—	JP Morgan	Hardik Parikh	PT Cut	Overweight	$75→$65
—	Canaccord Genuity	Edward Nash	PT Raise	Buy	$107→$114
—	Lake Street	Daniel Brims	Initiate	Buy	$89
—	BTIG	Jeet Mukherjee	Maintained	Buy	$125
—	Cantor Fitzgerald	Steve Seedhouse	PT Cut	Overweight	$105→$100
—	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$102
—	Canaccord Genuity	Edward Nash	PT Raise	Buy	$106→$107
—	Canaccord Genuity	Edward Nash	Initiate	Buy	$106
—	JP Morgan	Hardik Parikh	PT Cut	Overweight	$80→$75
—	Morgan Stanley	Michael Ulz	PT Raise	Overweight	$98→$102
—	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$102
—	BTIG	Justin Zelin	Maintained	Buy	$125
—	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$102
—	Raymond James	Ryan Deschner	PT Cut	Strong Buy	$125→$122
—	Citigroup	David Lebowitz	PT Raise	Neutral	$31→$38

Viking Therapeutics Inc

Viking Therapeutics (VKTX) Stock Price Target 2026

Latest Upgrades and Downgrades for Viking Therapeutics Stock

Viking Therapeutics (VKTX) Stock Price Target 2026

Latest Upgrades and Downgrades for Viking Therapeutics Stock

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118

PRO
Canaccord Genuity Maintains Buy on Viking Therapeutics, Lowers Price Target to $106

PRO
UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87

PRO
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118

PRO
Canaccord Genuity Maintains Buy on Viking Therapeutics, Lowers Price Target to $106

PRO
UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87

PRO
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

Viking Therapeutics Inc

Viking Therapeutics (VKTX) Stock Price Target 2026

Latest Upgrades and Downgrades for Viking Therapeutics Stock

Viking Therapeutics (VKTX) Stock Price Target 2026

Latest Upgrades and Downgrades for Viking Therapeutics Stock

Analyst Ratings News

PROCanaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118

PROCanaccord Genuity Maintains Buy on Viking Therapeutics, Lowers Price Target to $106

PROUBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

PROTruist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

PROTruist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87

PROJP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

People Also Watch

People Also Watch

Analyst Ratings News

PROCanaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118

PROCanaccord Genuity Maintains Buy on Viking Therapeutics, Lowers Price Target to $106

PROUBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

PROTruist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

PROTruist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87

PROJP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

PRO
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118

PRO
Canaccord Genuity Maintains Buy on Viking Therapeutics, Lowers Price Target to $106

PRO
UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87

PRO
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

PRO
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118

PRO
Canaccord Genuity Maintains Buy on Viking Therapeutics, Lowers Price Target to $106

PRO
UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Lowers Price Target to $85

PRO
Truist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87

PRO
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65